The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 30, 2025

Filed:

Apr. 11, 2018
Applicants:

The Johns Hopkins University, Baltimore, MD (US);

Adarga, Llc, Baltimore, MD (US);

Inventors:

Barbara Slusher, Kingsville, MD (US);

Michael Nedelcovych, Arlington, VA (US);

Rana Rais, West Friendship, MD (US);

Clemens Kratochwil, Hirschberg, DE;

Assignees:

The Johns Hopkins University, Baltimore, MD (US);

Adarga, LLC, Baltimore, MD (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 31/662 (2006.01); A61K 31/664 (2006.01); A61K 51/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/662 (2013.01); A61K 31/664 (2013.01); A61K 51/0402 (2013.01); A61K 51/0497 (2013.01);
Abstract

The use of a class of prodrugs of 2-PMPA that alter tissue distribution of 2-PMPA to non-prostate tissues is disclosed. The presently disclosed prodrugs preferentially distribute to healthy tissues including the kidney, lacrimal glands, and salivary glands, which represent sites of off-target binding and toxicity for PSMA-targeted prostate cancer imaging agents and therapies. Accordingly, the 2-PMPA prodrugs can be used to pretreat, bind to, and shield the kidney and salivary glands from PSMA-targeted cytotoxic or radiotherapy.


Find Patent Forward Citations

Loading…